Skip to main content
SpringerLink
Log in

Characteristics and Treatment of Painful Diabetic Neuropathy

  • Chapter
  • First Online:
Diabetic Neuropathy

Part of the book series: Contemporary Diabetes ((CDI))

  • 780 Accesses

Abstract

The most common of painful diabetic neuropathies is painful polyneuropathy, affecting up to 50% of patients with polyneuropathy. The risk factors for developing neuropathic pain in those with diabetic polyneuropathy are largely unknown. Increasing evidence point toward an association between pain and neuropathy severity, but studies also suggest that other risk factors, such as female sex and high HbA1c, are also involved. The symptoms of painful diabetic polyneuropathy can be a shooting, squeezing, or burning pain in the feet, often together with other abnormal sensations, such as numbness or pins and needles. The diagnosis of painful diabetic neuropathy is primarily clinical, consisting of evaluation of symptoms and signs, and can be confirmed with abnormal nerve conduction studies or intraepidermal nerve fiber density. The management of painful diabetic polyneuropathy consists of symptomatic pain treatment including nonpharmacological treatment, such as pain education, physiotherapy, and psychological treatment and pharmacological treatment to improve quality of life. According to guideline recommendations, pregabalin and gabapentin, tricyclic antidepressants, and serotonin noradrenaline reuptake inhibitors are recommended as a first-line therapy with a strong recommendation and moderate to high quality of evidence. Effect sizes are moderate and not all patients experience an effect in tolerated doses and often combination treatment and a multidisciplinary approach to treatment is needed.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 159.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Izenberg A, Perkins BA, Bril V. Diabetic neuropathies. Semin Neurol. 2015;35:424–30.

    Article  PubMed  Google Scholar 

  2. Gylfadottir SS, Weeracharoenkul D, Andersen ST, Niruthisard S, Suwanwalaikorn S, Jensen TS. Painful and non-painful diabetic polyneuropathy: clinical characteristics and diagnostic issues. J Diabetes Investig. 2019;10:1148–57.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Raja SN, Carr DB, Cohen M, et al. The revised International Association for the Study of Pain definition of pain: concepts, challenges, and compromises. Pain. 2020;161:1976.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Taxonomy I. https://www.iasp-pain.org/terminology?navItemNumber=576

  5. Tesfaye S, Boulton AJ, Dyck PJ, et al. Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments. Diabetes Care. 2010;33:2285–93.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Callaghan BC, Cheng HT, Stables CL, Smith AL, Feldman EL. Diabetic neuropathy: clinical manifestations and current treatments. Lancet Neurol. 2012;11:521–34.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Themistocleous AC, Ramirez JD, Shillo PR, et al. The Pain in Neuropathy Study (PiNS): a cross-sectional observational study determining the somatosensory phenotype of painful and painless diabetic neuropathy. Pain. 2016;157:1132–45.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Abbott CA, Malik RA, van Ross ER, Kulkarni J, Boulton AJ. Prevalence and characteristics of painful diabetic neuropathy in a large community-based diabetic population in the U.K. Diabetes Care. 2011;34:2220–4.

    Article  PubMed  PubMed Central  Google Scholar 

  9. Andersen ST, Witte DR, Dalsgaard EM, et al. Risk factors for incident diabetic polyneuropathy in a cohort with screen-detected type 2 diabetes followed for 13 years: addition-Denmark. Diabetes Care. 2018;41:1068–75.

    Article  CAS  PubMed  Google Scholar 

  10. Gylfadottir SS, et al. Diagnosis and prevalence of diabetic polyneuropathy: a cross-sectional study of Danish patients with type 2 diabetes. Eur J Neurol. 2020;27:2575.

    Article  CAS  PubMed  Google Scholar 

  11. van Hecke O, Austin SK, Khan RA, Smith BH, Torrance N. Neuropathic pain in the general population: a systematic review of epidemiological studies. Pain. 2014;155:654–62.

    Article  PubMed  Google Scholar 

  12. Feldman EL, Callaghan BC, Pop-Busui R, et al. Diabetic neuropathy. Nat Rev Dis Primers. 2019;5:41.

    Article  PubMed  Google Scholar 

  13. Bonhof GJ, Herder C, Strom A, Papanas N, Roden M, Ziegler D. Emerging biomarkers, tools, and treatments for diabetic polyneuropathy. Endocr Rev. 2019;40:153–92.

    Article  PubMed  Google Scholar 

  14. Partanen J, Niskanen L, Lehtinen J, Mervaala E, Siitonen O, Uusitupa M. Natural history of peripheral neuropathy in patients with non-insulin-dependent diabetes mellitus. N Engl J Med. 1995;333:89–94.

    Article  CAS  PubMed  Google Scholar 

  15. Ziegler D, Strom A, Lobmann R, Reiners K, Rett K, Schnell O. High prevalence of diagnosed and undiagnosed polyneuropathy in subjects with and without diabetes participating in a nationwide educational initiative (PROTECT study). J Diabetes Complicat. 2015;29:998–1002.

    Article  Google Scholar 

  16. Truini A, Spallone V, Morganti R, et al. A cross sectional study investigating frequency and features of definitely diagnosed diabetic painful polyneuropathy. Pain. 2018;159:2658.

    Article  PubMed  Google Scholar 

  17. Van Acker K, Bouhassira D, De Bacquer D, et al. Prevalence and impact on quality of life of peripheral neuropathy with or without neuropathic pain in type 1 and type 2 diabetic patients attending hospital outpatients clinics. Diabetes Metab. 2009;35:206–13.

    Article  PubMed  Google Scholar 

  18. Aslam A, Singh J, Rajbhandari S. Prevalence of painful diabetic neuropathy using the self-completed Leeds assessment of neuropathic symptoms and signs questionnaire in a population with diabetes. Can J Diabetes. 2015;39:285–95.

    Article  PubMed  Google Scholar 

  19. Bouhassira D, Letanoux M, Hartemann A. Chronic pain with neuropathic characteristics in diabetic patients: a French cross-sectional study. PLoS One. 2013;8:e74195.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Finnerup NB, Kuner R, Jensen TS. Neuropathic pain: from mechanisms to treatment. Physiol Rev. 2020;101:259.

    Article  PubMed  Google Scholar 

  21. Finnerup NB, Haroutounian S, Kamerman P, et al. Neuropathic pain: an updated grading system for research and clinical practice. Pain. 2016;157:1599.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Treede RD, Jensen TS, Campbell JN, et al. Neuropathic pain: redefinition and a grading system for clinical and research purposes. Neurology. 2008;70:1630–5.

    Article  CAS  PubMed  Google Scholar 

  23. Attal N, Bouhassira D, Baron R. Diagnosis and assessment of neuropathic pain through questionnaires. Lancet Neurol. 2018;17:456–66.

    Article  PubMed  Google Scholar 

  24. Bouhassira D, Attal N, Alchaar H, et al. Comparison of pain syndromes associated with nervous or somatic lesions and development of a new neuropathic pain diagnostic questionnaire (DN4). Pain. 2005;114:29–36.

    Article  PubMed  Google Scholar 

  25. Spallone V, Morganti R, D’Amato C, Greco C, Cacciotti L, Marfia GA. Validation of DN4 as a screening tool for neuropathic pain in painful diabetic polyneuropathy. Diabet Med. 2012;29:578–85.

    Article  CAS  PubMed  Google Scholar 

  26. Bouhassira D, Attal N, Fermanian J, et al. Development and validation of the neuropathic pain symptom inventory. Pain. 2004;108:248–57.

    Article  PubMed  Google Scholar 

  27. Jensen MP, Karoly P, Braver S. The measurement of clinical pain intensity: a comparison of six methods. Pain. 1986;27:117–26.

    Article  PubMed  Google Scholar 

  28. Spallone V, Greco C. Painful and painless diabetic neuropathy: one disease or two? Curr Diab Rep. 2013;13:533–49.

    Article  CAS  PubMed  Google Scholar 

  29. Shillo P, Sloan G, Greig M, et al. Painful and painless diabetic neuropathies: what is the difference? Curr Diab Rep. 2019;19:32.

    Article  PubMed  PubMed Central  Google Scholar 

  30. Tesfaye S, Boulton AJ, Dickenson AH. Mechanisms and management of diabetic painful distal symmetrical polyneuropathy. Diabetes Care. 2013;36:2456–65.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Davies M, Brophy S, Williams R, Taylor A. The prevalence, severity, and impact of painful diabetic peripheral neuropathy in type 2 diabetes. Diabetes Care. 2006;29:1518–22.

    Article  PubMed  Google Scholar 

  32. Raputova J, Srotova I, Vlckova E, et al. Sensory phenotype and risk factors for painful diabetic neuropathy: a cross-sectional observational study. Pain. 2017;158:2340–53.

    Article  PubMed  PubMed Central  Google Scholar 

  33. Gylfadottir SS, Christensen DH, Nicolaisen SK, et al. Diabetic polyneuropathy and pain, prevalence, and patient characteristics: a cross-sectional questionnaire study of 5,514 patients with recently diagnosed type 2 diabetes. Pain. 2019;161:574.

    Article  PubMed Central  Google Scholar 

  34. Hebert HL, Veluchamy A, Torrance N, Smith BH. Risk factors for neuropathic pain in diabetes mellitus. Pain. 2016;158:560.

    Article  PubMed Central  Google Scholar 

  35. Naranjo C, Del Reguero L, Moratalla G, Hercberg M, Valenzuela M, Failde I. Anxiety, depression and sleep disorders in patients with diabetic neuropathic pain: a systematic review. Expert Rev Neurother. 2019;19:1201–9.

    Article  CAS  PubMed  Google Scholar 

  36. Gore M, Brandenburg NA, Dukes E, Hoffman DL, Tai KS, Stacey B. Pain severity in diabetic peripheral neuropathy is associated with patient functioning, symptom levels of anxiety and depression, and sleep. J Pain Symptom Manag. 2005;30:374–85.

    Article  Google Scholar 

  37. D’Amato C, Morganti R, Greco C, et al. Diabetic peripheral neuropathic pain is a stronger predictor of depression than other diabetic complications and comorbidities. Diab Vasc Dis Res. 2016;13:418–28.

    Article  PubMed  Google Scholar 

  38. Gylfadottir SS, Christensen DH, Nicolaisen SK, et al. Diabetic polyneuropathy and pain, prevalence, and patient characteristics: a cross-sectional questionnaire study of 5,514 patients with recently diagnosed type 2 diabetes. Pain. 2020;161:574–83.

    Article  PubMed  Google Scholar 

  39. Kioskli K, Scott W, Winkley K, Kylakos S, McCracken LM. Psychosocial factors in painful diabetic neuropathy: a systematic review of treatment trials and survey studies. Pain Med. 2019;20:1756–73.

    Article  PubMed  Google Scholar 

  40. Geelen CC, Smeets R, Schmitz S, van den Bergh JP, Goossens M, Verbunt JA. Anxiety affects disability and quality of life in patients with painful diabetic neuropathy. Eur J Pain. 2017;21:1632–41.

    Article  CAS  PubMed  Google Scholar 

  41. Finnerup NB. Nonnarcotic methods of pain management. N Engl J Med. 2019;380:2440–8.

    Article  CAS  PubMed  Google Scholar 

  42. Scascighini L, Toma V, Dober-Spielmann S, Sprott H. Multidisciplinary treatment for chronic pain: a systematic review of interventions and outcomes. Rheumatology (Oxford). 2008;47:670–8.

    Article  CAS  PubMed  Google Scholar 

  43. Sloan G, Shillo P, Selvarajah D, et al. A new look at painful diabetic neuropathy. Diabetes Res Clin Pract. 2018;144:177–91.

    Article  PubMed  Google Scholar 

  44. Shaygan M, Böger A, Kröner-Herwig B. Predicting factors of outcome in multidisciplinary treatment of chronic neuropathic pain. J Pain Res. 2018;11:2433–43.

    Article  PubMed  PubMed Central  Google Scholar 

  45. Calcutt NA. Diabetic neuropathy and neuropathic pain: a (con)fusion of pathogenic mechanisms? Pain. 2020;161:S65–s86.

    Article  PubMed  PubMed Central  Google Scholar 

  46. Tesfaye S, Vileikyte L, Rayman G, et al. Painful diabetic peripheral neuropathy: consensus recommendations on diagnosis, assessment and management. Diabetes Metab Res Rev. 2011;27:629–38.

    Article  CAS  PubMed  Google Scholar 

  47. Boulton AJ, Drury J, Clarke B, Ward JD. Continuous subcutaneous insulin infusion in the management of painful diabetic neuropathy. Diabetes Care. 1982;5:386–90.

    Article  CAS  PubMed  Google Scholar 

  48. Callaghan BC, Little AA, Feldman EL, Hughes RA. Enhanced glucose control for preventing and treating diabetic neuropathy. Cochrane Database Syst Rev. 2012;6:CD007543.

    PubMed  Google Scholar 

  49. Ishibashi F, Taniguchi M, Kosaka A, Uetake H, Tavakoli M. Improvement in neuropathy outcomes with normalizing HbA(1c) in patients with type 2 diabetes. Diabetes Care. 2019;42:110–8.

    Article  CAS  PubMed  Google Scholar 

  50. Papanas N, Ziegler D. Emerging drugs for diabetic peripheral neuropathy and neuropathic pain. Expert Opin Emerg Drugs. 2016;21:393–407.

    Article  CAS  Google Scholar 

  51. Papanas N, Ziegler D. Efficacy of alpha-lipoic acid in diabetic neuropathy. Expert Opin Pharmacother. 2014;15:2721–31.

    Article  CAS  Google Scholar 

  52. Zhang BY, Zhang YL, Sun Q, et al. Alpha-lipoic acid downregulates TRPV1 receptor via NF-κB and attenuates neuropathic pain in rats with diabetes. CNS Neurosci Ther. 2020;26:762–72.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  53. Ziegler D, Nowak H, Kempler P, Vargha P, Low PA. Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a meta-analysis. Diabet Med. 2004;21:114–21.

    Article  CAS  PubMed  Google Scholar 

  54. Ziegler D, Edmundson S, Gurieva I, Mankovsky B, Papanas N, Strokov I. Predictors of response to treatment with actovegin for 6 months in patients with type 2 diabetes and symptomatic polyneuropathy. J Diabetes Complicat. 2017;31:1181–7.

    Article  Google Scholar 

  55. Ziegler D, Movsesyan L, Mankovsky B, Gurieva I, Abylaiuly Z, Strokov I. Treatment of symptomatic polyneuropathy with actovegin in type 2 diabetic patients. Diabetes Care. 2009;32:1479–84.

    Article  CAS  PubMed Central  Google Scholar 

  56. Fukuoka M, Sakurai K, Ohta T, Kiyoki M, Katayama I. Tacalcitol, an active vitamin D3, induces nerve growth factor production in human epidermal keratinocytes. Skin Pharmacol Appl Ski Physiol. 2001;14:226–33.

    Article  CAS  Google Scholar 

  57. Shillo P, Selvarajah D, Greig M, et al. Reduced vitamin D levels in painful diabetic peripheral neuropathy. Diabet Med. 2019;36:44–51.

    Article  CAS  PubMed  Google Scholar 

  58. Yammine K, Wehbe R, Assi C. A systematic review on the efficacy of vitamin D supplementation on diabetic peripheral neuropathy. Clin Nutr. 2020;39:2970–4.

    Article  CAS  Google Scholar 

  59. Finnerup NB, Attal N, Haroutounian S, et al. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. Lancet Neurol. 2015;14:162–73.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  60. Attal N, Cruccu G, Baron R, et al. EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision. Eur J Neurol. 2010;17:1113–e1188.

    Article  CAS  PubMed  Google Scholar 

  61. Bril V, England J, Franklin GM, et al. Evidence-based guideline: treatment of painful diabetic neuropathy: report of the American Academy of Neurology, the American Association of Neuromuscular and Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation. Neurology. 2011;76:1758–65.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  62. Agency for Health Research and Quality (AHRQ). Accessed 15 Jan 2021.

    Google Scholar 

  63. Waldfogel JM, Nesbit SA, Dy SM, et al. Pharmacotherapy for diabetic peripheral neuropathy pain and quality of life: a systematic review. Neurology. 2017;88:1958–67.

    Article  CAS  PubMed  Google Scholar 

  64. Enomoto H, Yasuda H, Nishiyori A, et al. Duloxetine in patients with diabetic peripheral neuropathic pain in Japan: a randomized, doubleblind, noninferiority comparative study with pregabalin. J Pain Res. 2018;11:1857–68.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  65. Tesfaye S, Wilhelm S, Lledo A, et al. Duloxetine and pregabalin: high-dose monotherapy or their combination? The “COMBO-DN study”--a multinational, randomized, double-blind, parallel-group study in patients with diabetic peripheral neuropathic pain. Pain. 2013;154:2616–25.

    Article  CAS  PubMed  Google Scholar 

  66. Finnerup NB. Add-on therapy: when two are not better than one. Pain. 2013;154:2579–80.

    Article  PubMed  Google Scholar 

  67. Kremer M, Salvat E, Muller A, Yalcin I, Barrot M. Antidepressants and gabapentinoids in neuropathic pain: mechanistic insights. Neuroscience. 2016;338:183–206.

    Article  CAS  PubMed  Google Scholar 

  68. Javed S, Alam U, Malik RA. Burning through the pain: treatments for diabetic neuropathy. Diabetes Obes Metab. 2015;17:1115–25.

    Article  CAS  PubMed  Google Scholar 

  69. Sindrup SH, Otto M, Finnerup NB, Jensen TS. Antidepressants in the treatment of neuropathic pain. Basic Clin Pharmacol Toxicol. 2005;96:399–409.

    Article  CAS  PubMed  Google Scholar 

  70. Gillving M, Demant D, Holbech JV, et al. A randomized, controlled trial of a β2-agonist in painful polyneuropathy. Pain. 2020;162:1364.

    Article  Google Scholar 

  71. Gillman PK. Tricyclic antidepressant pharmacology and therapeutic drug interactions updated. Br J Pharmacol. 2007;151:737–48.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  72. American Geriatrics Society. Updated beers criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2015;2015(63):2227–46.

    Google Scholar 

  73. Ray WA, Meredith S, Thapa PB, Hall K, Murray KT. Cyclic antidepressants and the risk of sudden cardiac death. Clin Pharmacol Ther. 2004;75:234–41.

    Article  CAS  PubMed  Google Scholar 

  74. Evoy KE, Sadrameli S, Contreras J, Covvey JR, Peckham AM, Morrison MD. Abuse and misuse of pregabalin and gabapentin: a systematic review update. Drugs. 2020;81:125.

    Article  Google Scholar 

  75. Franklin GM. Opioids for chronic noncancer pain: a position paper of the American Academy of Neurology. Neurology. 2014;83:1277–84.

    Article  CAS  PubMed  Google Scholar 

  76. Dowell D, Haegerich TM, Chou R. CDC guideline for prescribing opioids for chronic pain--United States, 2016. JAMA. 2016;315:1624–45.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  77. Hoffman EM, Watson JC, St Sauver J, Staff NP, Klein CJ. Association of Long-term Opioid Therapy With Functional Status, adverse outcomes, and mortality among patients with polyneuropathy. JAMA Neurol. 2017;74:773–9.

    Article  PubMed  PubMed Central  Google Scholar 

  78. Ballantyne JCBS, Blyth F, Cordosa M, Finley A, Furlan A, et al. https://www.iasp-pain.org/Advocacy/OpioidPositionStatement.2018. Accessed 19 Jan 2021.

  79. Demant DT, Lund K, Vollert J, et al. The effect of oxcarbazepine in peripheral neuropathic pain depends on pain phenotype: a randomised, double-blind, placebo-controlled phenotype-stratified study. Pain. 2014;155:2263–73.

    Article  CAS  PubMed  Google Scholar 

  80. Fisher E, Moore RA, Fogarty AE, et al. Cannabinoids, cannabis, and cannabis-based medicine for pain management: a systematic review of randomised controlled trials. Pain. 2020;162:S45.

    Google Scholar 

  81. Moore RA, Fisher E, Finn DP, et al. Cannabinoids, cannabis, and cannabis-based medicines for pain management: an overview of systematic reviews. Pain. 2020;162:S67.

    Google Scholar 

  82. Attal N, Bouhassira D. Translational neuropathic pain research. Pain. 2019;160(Suppl 1):S23–s28.

    Article  PubMed  Google Scholar 

  83. Yekkirala AS, Roberson DP, Bean BP, Woolf CJ. Breaking barriers to novel analgesic drug development. Nat Rev Drug Discov. 2017;16:545–64.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  84. Rice ASC, Dworkin RH, McCarthy TD, et al. EMA401, an orally administered highly selective angiotensin II type 2 receptor antagonist, as a novel treatment for postherpetic neuralgia: a randomised, double-blind, placebo-controlled phase 2 clinical trial. Lancet. 2014;383:1637–47.

    Article  CAS  PubMed  Google Scholar 

  85. Apfel SC, Schwartz S, Adornato BT, et al. Efficacy and safety of recombinant human nerve growth factor in patients with diabetic polyneuropathy: a randomized controlled trial. rhNGF Clinical Investigator Group. JAMA. 2000;284:2215–21.

    Article  CAS  PubMed  Google Scholar 

  86. Bramson C, Herrmann DN, Carey W, et al. Exploring the role of tanezumab as a novel treatment for the relief of neuropathic pain. Pain Med. 2015;16:1163–76.

    Article  PubMed  Google Scholar 

  87. Eccleston C, Hearn L, Williams AC. Psychological therapies for the management of chronic neuropathic pain in adults. Cochrane Database Syst Rev. 2015;2015:CD011259.

    PubMed  PubMed Central  Google Scholar 

  88. Hayes SC, Luoma JB, Bond FW, Masuda A, Lillis J. Acceptance and commitment therapy: model, processes and outcomes. Behav Res Ther. 2006;44:1–25.

    Article  PubMed  Google Scholar 

  89. Kioskli K, Scott W, Winkley K, Godfrey E, McCracken LM. Online acceptance and commitment therapy for people with painful diabetic neuropathy in the United Kingdom: a single-arm feasibility trial. Pain Med. 2020;21:2777–88.

    Article  PubMed  PubMed Central  Google Scholar 

  90. Williams ACC, Fisher E, Hearn L, Eccleston C. Psychological therapies for the management of chronic pain (excluding headache) in adults. Cochrane Database Syst Rev. 2020;8:CD007407.

    PubMed  Google Scholar 

  91. Akyuz G, Kenis O. Physical therapy modalities and rehabilitation techniques in the management of neuropathic pain. Am J Phys Med Rehabil. 2014;93:253–9.

    Article  PubMed  Google Scholar 

  92. Brod M, Pohlman B, Blum SI, Ramasamy A, Carson R. Burden of illness of diabetic peripheral neuropathic pain: a qualitative study. Patient. 2015;8:339–48.

    Article  PubMed  Google Scholar 

  93. Jesson T, Runge N, Schmid AB. Physiotherapy for people with painful peripheral neuropathies: a narrative review of its efficacy and safety. Pain Rep. 2020;5:1–e834.

    Article  Google Scholar 

  94. Singleton JR, Smith AG, Marcus RL. Exercise as therapy for diabetic and prediabetic neuropathy. Curr Diab Rep. 2015;15:120.

    Article  PubMed  Google Scholar 

  95. Davies B, Cramp F, Gauntlett-Gilbert J, Wynick D, McCabe CS. The role of physical activity and psychological coping strategies in the management of painful diabetic neuropathy--a systematic review of the literature. Physiotherapy. 2015;101:319–26.

    Article  PubMed  Google Scholar 

  96. Baute V, Zelnik D, Curtis J, Sadeghifar F. Complementary and alternative medicine for painful peripheral neuropathy. Curr Treat Options Neurol. 2019;21:44.

    Article  PubMed  Google Scholar 

  97. van Laake-Geelen CCM, Smeets R, Quadflieg S, Kleijnen J, Verbunt JA. The effect of exercise therapy combined with psychological therapy on physical activity and quality of life in patients with painful diabetic neuropathy: a systematic review. Scand J Pain. 2019;19:433–9.

    Article  PubMed  Google Scholar 

  98. Cruccu G, Garcia-Larrea L, Hansson P, et al. EAN guidelines on central neurostimulation therapy in chronic pain conditions. Eur J Neurol. 2016;23:1489.

    Article  CAS  PubMed  Google Scholar 

  99. Amato Nesbit S, Sharma R, Waldfogel JM, et al. Non-pharmacologic treatments for symptoms of diabetic peripheral neuropathy: a systematic review. Curr Med Res Opin. 2019;35:15–25.

    Article  PubMed  Google Scholar 

  100. Gibson W, Wand BM, O’Connell NE. Transcutaneous electrical nerve stimulation (TENS) for neuropathic pain in adults. Cochrane Database Syst Rev. 2017;9:CD011976.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Clinical Medicine, Danish Pain Research Center, Aarhus University, Aarhus, Denmark

    Sandra Sif Gylfadottir & Nanna Brix Finnerup

  2. Department of Neurology, Aarhus University Hospital, Aarhus, Denmark

    Sandra Sif Gylfadottir & Nanna Brix Finnerup

Authors
  1. Sandra Sif Gylfadottir
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Nanna Brix Finnerup
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sandra Sif Gylfadottir .

Editor information

Editors and Affiliations

  1. Royal Hallamshire Hospital, Sheffield Teaching Hospitals and the University of Sheffield Director of Diabetes Research, Sheffield, UK

    Solomon Tesfaye

  2. Beth Israel Deaconess Medical Center, Boston, MA, USA

    Christopher H. Gibbons

  3. Weill Cornell Medicine, Cornell University, Doha, Qatar

    Rayaz Ahmed Malik

  4. Department of Surgery, Beth Israel Deaconess Medical Center, Boston, MA, USA

    Aristidis Veves

Rights and permissions

Reprints and permissions

Copyright information

© 2023 The Author(s), under exclusive license to Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Gylfadottir, S.S., Finnerup, N.B. (2023). Characteristics and Treatment of Painful Diabetic Neuropathy. In: Tesfaye, S., Gibbons, C.H., Malik, R.A., Veves, A. (eds) Diabetic Neuropathy. Contemporary Diabetes. Humana, Cham. https://doi.org/10.1007/978-3-031-15613-7_25

Download citation

  • DOI: https://doi.org/10.1007/978-3-031-15613-7_25

  • Published:

  • Publisher Name: Humana, Cham

  • Print ISBN: 978-3-031-15612-0

  • Online ISBN: 978-3-031-15613-7

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation